Berget Cari, Cobry Erin, Escobar Estella, Towers Lindsey, Sakomoto Casey, Taylor Kasserine, Trojanowski Paige J, Wadwa R Paul, Forlenza Gregory P
Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA.
Colorado School of Public Health, University of Colorado, Aurora, Colorado, USA.
Diabetes Obes Metab. 2025 Sep;27(9):4942-4949. doi: 10.1111/dom.16538. Epub 2025 Jun 24.
Glycaemic benefits of automated insulin delivery for youth with type 1 diabetes (T1D) are well established; however, additional data on psychosocial impacts are needed. The study aims to evaluate the real-world glycaemic and psychosocial impacts for youth with T1D using the Omnipod 5 AID system for 1 year.
One hundred forty-one youth who were prescribed the Omnipod 5 AID system for their diabetes care were enrolled in a prospective, observational study. Youth and caregivers completed the hypoglycaemia fear survey (HFS), insulin delivery systems: perceptions, ideas, reflections and expectations survey (INSPIRE) and the problem areas in diabetes survey (PAID) to assess psychosocial impacts. Insulin pump and glycaemic data were collected from Glooko.
A1c (HbA1c) improved from 7.5% (0.9%) at baseline to 7.1% (0.1%) at month 12 (p < 0.001). Time in Range (TIR) increased from 58.3% (2.8%) to 64.0 (1.4%) (p < 0.001) and time below range (TBR) <70 mg/dL decreased from 3.1% (0.2%) to 2.1% (0.2%) (p < 0.001). Caregivers reported improvements in all psychosocial measures. From baseline to month 12, INSPIRE scores improved from 77.4 (1.4) to 83.6 (1.4), HFS scores improved in all three subscales and PAID scores improved from 53.3 (1.7) to 44.2 (1.8) (p < 0.001). Youth reported improvements in HFS scores in all three subscales, and PAID scores improved from 51.9 (2.8) to 46.9 (2.9) (p < 0.001). There was no change in INSPIRE scores.
This study demonstrates sustained improvements in glycaemic and psychosocial outcomes for youth and caregivers using the Omnipod 5 AID system for 12 months, the longest real-world evaluation of Omnipod 5 to date.
自动胰岛素给药对1型糖尿病（T1D）青少年的血糖益处已得到充分证实；然而，还需要关于心理社会影响的更多数据。本研究旨在评估使用Omnipod 5 AID系统1年对T1D青少年的实际血糖和心理社会影响。
141名因糖尿病护理而被处方使用Omnipod 5 AID系统的青少年参与了一项前瞻性观察研究。青少年和照顾者完成了低血糖恐惧调查（HFS）、胰岛素给药系统：认知、想法、反思和期望调查（INSPIRE）以及糖尿病问题领域调查（PAID），以评估心理社会影响。胰岛素泵和血糖数据从Glooko收集。
糖化血红蛋白（HbA1c）从基线时的7.5%（0.9%）改善至第12个月时的7.1%（0.1%）（p < 0.001）。血糖达标时间（TIR）从58.3%（2.8%）增加到64.0（1.4%）（p < 0.001），血糖低于范围（TBR）<70mg/dL的时间从3.1%（0.2%）降至2.1%（0.2%）（p < 0.001）。照顾者报告所有心理社会指标均有改善。从基线到第12个月，INSPIRE评分从77.4（1.4）提高到83.6（1.4），HFS所有三个子量表的评分均有所改善，PAID评分从53.3（1.7）降至44.2（1.8）（p < 0.001）。青少年报告HFS所有三个子量表的评分均有所改善，PAID评分从51.9（2.8）降至46.9（2.9）（p < 0.001）。INSPIRE评分无变化。
本研究表明，使用Omnipod 5 AID系统12个月，青少年和照顾者的血糖及心理社会结局持续改善，这是迄今为止对Omnipod 5最长时间的实际评估。
